-
2019-nCoV Spike protein S1 (T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H)
2019-nCoV Spike protein S1 (T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H)
- 中文名称：
- 2019-nCoV Spike protein S1 (T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H)
- 英文名称：
- 2019-nCoV Spike protein S1 (T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H)
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA73330
- 规格：
- 0.01 mg|0.02 mg|0.05 mg|0.1 mg|2x0.1 mg
- 保存建议：
- Store product at -70 degree C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
- 货期：
- 6-8周
- 纯度：
- N/A
- 产品形式：
- Recombinant protein stored in 50mM sodium phosphate, pH7.5, 300mM NaCl, 150mM imidazole.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Recombinant 2019-nCoV Spike protein S1 (T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H) was expressed in CHO cells using a C-terminal His-tag. The gene accession number is MN908947.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains the most rapidly spreading disease since 2020. The spike glycoprotein (S) of coronavirus, a type I transmembrane protein containing two subunits S1 and S2, facilitates viral genome entry into the host cells through the interaction with angiotensin-converting enzyme 2 (ACE2)(1). The B.1.621 variant emerged from the parental B.1 lineage. It was first found in Colombia in January 2021, and the World Health Organization (WHO) designated the variant as Mu in August 2021(2). Compared to Delta, the Mu variant shows enhanced immune resistance to antibodies, and the E484K mutation, an escape mutation, is considered to be the reason for reducing the neutralizing ability of antibodies (3). As more variants of the virus emerge, it is pivotal to study the transmissibility, virulence, and their possible tendency to escape antibody neutralization of the virus (4).
